The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
MRI is particularly valuable in pediatric care due to its non-invasive nature
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
The topical fluralaner solution is cleared for the prevention and treatment of new world screwworm infestation
Growing patent filings and tier-2 innovators reflect expanding national research base
Subscribe To Our Newsletter & Stay Updated
